Craft
  • Home
  •  / Kamada Pharmaceuticals
Kamada Pharmaceuticals

Kamada Pharmaceuticals

Revenue

$103.6 M

FY, 2021

Market Capitalization

$213.3 M

2022-09-19

Kamada Pharmaceuticals Summary

Company summary

Overview
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. It uses its proprietary platform technology for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a liquid form as well as other plasma-derived Immune globulins. The company offers a line of pharmaceutical products intended for administration by injection or infusion.
Type
Public
Founded
1990
HQ
Rehovot, IL | view all locations
Website
https://www.kamada.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Amir London

    Amir London, CEO

    • Chaime Orlev
    • Michal Ayalon

      Michal Ayalon, VP, Research and Development

    • Eran Nir

    LocationsView all

    2 locations detected

    • Rehovot, Center District HQ

      Israel

    • Beit Kama, South District

      Israel

    Kamada Pharmaceuticals Financials

    Summary financials

    Revenue (Q2, 2022)
    $23.6M
    Gross profit (Q2, 2022)
    $10.3M
    Net income (Q2, 2022)
    ($3.9M)
    Cash (Q2, 2022)
    $29.9M
    EBIT (Q2, 2022)
    ($2.3M)
    Enterprise value
    $203.0M

    Footer menu